Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase IIb Open-label Trial of SUBA™-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)

NCT02354261 is registered in ClinicalTrials.gov with HedgePath Pharmaceuticals, Inc. as lead sponsor.

NCT NCT02354261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02354261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase IIb Open-label Trial of SUBA™-Itraconazole in Subjects With Basal Cell Carcinoma Nevus Syndrome (BCCNS)
Lead sponsor
HedgePath Pharmaceuticals, Inc.
Phase
Phase 2
Overall status
Completed
Start date
August 7, 2015
Completion date
March 31, 2019
Enrollment
38 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

basal cell carcinoma in basal cell nevus syndrome